We hypothesized that the inhibition of intracellular PAI‐1 activity would induce the detachment of CML‐LSCs in the BM, rendering CML‐LSCs susceptible to TKI therapy. The gene discussed is SERPINE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.